
Loading, please wait...

Loading, please wait...

The global antimicrobial resistance (AMR) crisis requires urgent innovation in diagnostic technology. Consequently, researchers have developed a Rapid Phenotypic AST platform that uses a dual-enzyme cascade colorimetric sensor (DECCS) to provide results within just five hours. This breakthrough significantly improves the speed of evidence-based antimicrobial prescribing.
Traditionally, phenotypic antimicrobial susceptibility testing (AST) takes 18 to 24 hours. This delay often forces clinicians to rely on empirical antibiotic treatments. Unfortunately, empirical therapy can compromise patient outcomes and accelerate the emergence of resistant strains. The DECCS system addresses this by transducing bacterial glucose metabolic activity into a quantitative colorimetric signal.
The sensor utilizes a glucose oxidase (GOD) and horseradish peroxidase (HRP) dual-enzyme cascade. When bacteria remain metabolically active, the system produces a visible color change. Clinicians can read these results with the naked eye or validate them using smartphone-based RGB analysis. Furthermore, microplate reader absorbance measurements provide an extra layer of analytical precision.
Researchers validated the performance of this platform using 155 clinical isolates and five reference strains. The pathogens tested included Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae. Remarkably, the sensor achieved 96% essential agreement and 98% categorical agreement with the gold-standard broth microdilution method.
This new method is particularly suitable for resource-limited clinical settings. It features a simplified workflow, low operational costs, and multiple readout capabilities. Therefore, it provides a practical alternative to strengthen antimicrobial stewardship efforts globally. By providing same-day results, the sensor helps clinicians optimize bacterial infection treatment and reduce unnecessary antibiotic use.
The DECCS method demonstrates high concordance with the gold standard, achieving 98% categorical agreement. However, it delivers these results in roughly 5 hours instead of the traditional 18-24 hour window.
Yes, the performance validation covered major pathogens from both groups, including Pseudomonas aeruginosa and Acinetobacter baumannii. It accurately identifies minimum inhibitory concentration (MIC) values for a variety of clinical isolates.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Zhang X et al. Bacterial Metabolism-Driven Dual-Enzyme Cascade Colorimetric Sensor for Antimicrobial Susceptibility Testing with Readily Interpretable Signals. Anal Chem. 2026 Mar 23. doi: 10.1021/acs.analchem.5c07762. PMID: 41867145.
Vasala A et al. Next-generation rapid phenotypic antimicrobial susceptibility testing. Lancet Infect Dis. 2024 Nov 09.
Tsalik EL et al. Emerging Technologies for Rapid Phenotypic Antimicrobial Susceptibility Testing of Clinical Isolates of Bacteria. Clin Microbiol Rev. 2022 Dec 01.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A new dual-enzyme sensor enables rapid phenotypic antimicrobial susceptibility testing in 5 hours, matching gold-standard accuracy for major pathogens....
5 months ago

A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today